Released Mar 17, 2026, after the close
10-Q filed Mar 17, 2026, 45 days after period end · 0001654954-26-002336
Q1 2026 · 10-Q
Revenue$2.29M$2.29M −7.1% vs Q1 2025+6.8% vs Q4 2025
Net Income$32.86K$32.86K +285.0% vs Q1 2025N/M vs Q4 2025
EPS Diluted$0.00$0.00 — vs Q1 2025no prior Q4 2025 on file
Gross Profit$722,374−6.0%
Operating Income-$94,535N/M
Operating Cash Flow-$390,139N/M
Free Cash Flowderived-$392,550N/M
Margins · derived
Gross margin31.5%+0.4 pt vs Q1 2025
Operating margin-4.1%−0.4 pt vs Q1 2025
Net margin1.4%+1.1 pt vs Q1 2025
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $2.29M | $2.47M | $2.38M | $4.24M |
| Net Income | $32.86K | $8.54K | -$270.72K | $426.43K |
| EPS Diluted | $0.00 | $0.00 | -$0.01 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR